Using combined autora~iography-immunocytochemistry, the anatomical distribution of [ H]naloxone-labelled opiate receptors was compared to the loci of neuronal systems immunoreactive for B -endorphin, [Leu]enkephalin and dynorphin A in rhesus monkey brain. High densities of binding were observed in relation to each of the systems, consistent with findings that each opioid precursor can synthesize one or more peptides with substantial (though not selective) activity at u receptors.
There is now impressive evidence for a multiplicity of functional roles of endogenous opioid peptides (I) , although much about their physiology and pathophysiology still remains obscure. This is particularly so for primates since most studies have focused upon rodents. While anatomical studies of opioid peptides and receptors have been useful in the formulation of specific hypotheses about the functions of opioid systems (e.g., [2] [3] [4] , only a few of these studies have been carried out in primates (2, (5) (6) (7) (8) .
Investigators of opioid systems must contend with the existence of three genetically distinct opioid peptide precursors (see ref. I for review) : proopiomelanocortin, which gives rise to B -endorphin; ~roenkephalin, which contains seven peptides with the [Met]-or LLeu]enkephalin active core; and prodynorphin, which produces three opioid ~ eptides ( a-neo-endorphin, dynorphin A, and dynorphin B) containing the Leu]enkephalin sequence. Enkephalin systems have been carefully mapped in rhesus monkey brain (7), but ~ -endorphin systems have been less well characterized (8) , and dynorphin systems have not been described at all in primate brain.
Recent autoradiographic studies have mapped the anatomical distribution of opiate receptors in monkey brain (5, 6) , although these investigations did not explore the differential distribution of receptor subtypes (2, 3, 9) for which the endogenous opioids show apparently different affinities (9) .
Given the complexity of endogenous opioid systems (i.e., different systems of neurons containing genetically distinct precursors giving rise to a variety of opioids which may act differentially at multiple receptors), it is essential to anatomically characterize these systems in relation to each other, including the receptors. We have been carrying out comparative autoradiographic-immunocytochemical studies of opioid systems in adjacent sections of rat brain (10) , and present here the results of such studies in rhesus monkey brain.
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Methods
Adult rhesus monkeys (Macaca mulatta) were anesthetized with sodium pentobarbital (30 mg/kg, i.v.), respirated, and perfused through the aorta with 2 liters of saline followed by 16 liters of 0.1M phosphate-buffered 4% formaldehyde.
Some animals were treated, under anesthesia, with colchicine (I-3 mg, intracerebroventricularly) 48 hours prior to perfusion. The brains were blocked, postfixed in buffered formaldehyde for 2-4 hours at 4°C, o incubated in buffered 15% sucrose overnight at 4 C, frozen in isopentane at o . o -50 C, sectioned at 20 microns in a cryostat at -20 C and thaw-mounted onto subbed slides which were then stored at -70°C.
Peroxidase-antiperoxidase immunocytochemistry was carried out as described (11), using antisera against proopiomelanocortin (POMC) peptides (B -endorphin, ACTH, and a -MSH), proenkephalin (ENK) peptides ([Leu]enkephalin and BAM-22P) and prodynorphin (DYN) peptides (dynorphin A and ~ -neo-endorphin). The characteristics of these antisera have been described elsewhere (4, 11, 12) ; preadsorption controls were also carried out as before (4, 11, 12) . Sections adjacent or near to those processed for immunocytochemistry were labelled with [ H]naloxone and processed for autoradiography as described elsewhere (3, IO, 13).
Results
When the anatomical distribution of E3H]naloxone-labelled sites was compared to the loci of immunoreactivity for the three classes of opioid peptides, we observed variations in binding site density with different opioid systems in different brain regions (Table I, Figure I ). The POMC system is anatomically associate~ with [ H]naloxone binding sites in many regions. High densities of [ H]naloxone binding were also observed in regions containing ENK and DYN (but not POMC) immunoreactive systems, e.g., in interpeduncular nucleus and the nucleus of the spinal tract of the trigeminal nerve, as well as in regions containing primarily DYN immunoreactivity (including perikarya), e.g., in supraoptic nucleus and paraventricular nucleus of hypothalamus.
In general, the POMC, ENK and DYN systems each showed a characteristic pattern of distribution which was consistent for each set of precursor-related antisera.
Discussion
We have detected a complex distribution of stereospecific
[3H]naloxone binding sites in formaldehyde-perfused rhesus monkey b~ain (Fig. I , Table I (I) .
However, the association between these sites and enkephalin immunoreactivity, as we reported previously for rat brain (10), does not fit the prediction based on the preferential affinity of the pentapeptide enkephalins for the 8 receptor (9) . This association is less paradoxical given the recent findings of substantial U activity of the enkephalin octapeptide (Kosterlitz, unpublished; Young 3et al., unpublished).
Similarly, the anatomical association between [ H]naloxone binding sites and dynorphin immunoreactivity might not have been predicted since dynorphin A has been reported to be a ~ ligand in vitro (e.g., 15); however dynorphin A(I-13) has been reported to interact with w sites under some conditions (16, 17, 18) , and dynorphin A(I-8), which is much more plentiful endogenously than dynorphin A (ref. 19) , also has considerable activity (18; Quirion and Weiss, unpublished). In short, given the capacity of each of the three opioid precursors to synthesize peptides with activity, it is not surprisiFn ~ to find an anatomical relationship between the three opioid systems and [ H]naloxone-labelled opiate receptors. This finding is consistent with the possibility that multiple products of the same opioid precursor act at different receptor subtypes, a viewpoint compatible with much recent evidence (I, 14, 20, 21 ; Quirion and Weiss, in preparation).
This viewpoint implies that opiate receptor subtypes will not be individually coupled to different endogenous opioid systems, but rather, that each system can express its activity through multiple receptors, and that peptide processing will be a key regulatory event in determining receptor subtype interactions.
